Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into a cooperation intention agreement with Illumina (NASDAQ: ILMN) at the 5th China International Import Expo (CIIE). The deal will lead to the introduction of Illumina’s latest NovaSeq X high throughput sequencer series products. Financial details of the agreement were not disclosed.
NovaSeq X Series Profile
The NovaSeq X Plus sequencer offers a sequencing flux 2.5 times that of the last-generation sequencer. Its reagent consumables can be transported at room temperature, enhancing logistical efficiency. The sequencer relies on ultra-high resolution optical elements and ultra-high density flow grooves, which improve accuracy by three times. Its integrated DRAGEN computing platform can achieve highly accurate fully automatic secondary analysis through five times of lossless data compression, significantly shortening the time for information processing and enabling a faster analysis process.
Sequanta Technologies Profile
Sequanta Technologies focuses on genomics, proteomics, and related services to support pharmaceutical clients in biomarker discovery and clinical trials. The company boasts a multi-omics analysis service platform, allowing for full process services ranging from preclinical biomarker exploration to post-marketing research. This collaboration with Illumina underscores Sequanta’s commitment to advancing multi-omics research and clinical services through cutting-edge technology.
Future Implications
The introduction of the NovaSeq X series in China is expected to enhance Sequanta Technologies’ capabilities in providing advanced sequencing services. This move aligns with the growing demand for high throughput sequencing in biomarker discovery and clinical trials, positioning Sequanta to play a pivotal role in the genomics and proteomics sectors.-Fineline Info & Tech
